Supplementary Methods, Supplementary References, Supplementary Tables 1-2, Supplementary Figures 1-3 from Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Table S1. Osimertinib, rociletinib, and afatinib permeability across Caco2 cell Monolayers; Supplementary Table S2. Strain information; Supplementary Figure S1. Structures of osimertinib (6), its plasma metabolites AZ5104 and AZ7550, rociletinib, gefitinib, and afatinib; Supplementary Figure S2. Representative whole body autoradiogram of section through a male Lister-hooded rat at 1 hour after single oral administration of [14C]osimertinib; Supplementary Figure S3. Tumor bioluminescence in a PC9 epidermal growth factor receptor exon 19 deletion mutation-positive mouse brain metastases model during treatment with gefitinib 6.25 mg/kg once daily (QD), or vehicle.
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362403905